Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Weight loss in patients with type 2 diabetes can improve glycemic control, lower blood pressure, and improve dyslipidemia. Glucagon-like peptide (GLP-1) receptor agonists are associated with weight loss and have potentially beneficial effects on cardiovascular risk biomarkers; however, there is limited information to indicate whether these effects remain outside of clinical trials. RESEARCH DESIGN AND METHODS: Medical records from the General Electric Centricity research database were analyzed retrospectively to evaluate the relationship between weight loss and glycemic control and changes in blood pressure and lipids in patients with type 2 diabetes initiating therapy with exenatide, sitagliptin, or insulin. Baseline and follow-up (90–365 days after the index date) for weight, A1C, fasting blood glucose (FBG), blood pressure, triglycerides, and LDL, HDL, and total cholesterol were assessed. RESULTS: A total of 6,280, 5,861, and 32,398 patients receiving exenatide, sitagliptin, or insulin, respectively, were included in the analysis. Exenatide-treated patients lost a mean ± SD of 3.0 ± 7.33 kg, sitagliptin-treated patients lost 1.1 ± 5.39 kg, and insulin-treated patients gained 0.6 ± 9.49 kg. There was a significant association between weight loss and a reduction in A1C and FBG with exenatide only and a reduction in blood pressure for all therapies. Weight loss was associated with some improvements in lipids, primarily in the GLP-1 receptor agonist group, with little association in the insulin group. CONCLUSIONS: Weight reduction with GLP-1 receptor agonists was associated with a shift toward a more favorable cardiovascular risk profile. Outcome trials are needed to determine whether improvement in biomarkers translates into a reduction in cardiovascular events in patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Better glycaemic control has been reported in T2D patients who have lost weight, and excess body weight is associated with the risk of cardiometabolic complications, which are major causes of morbidity and mortality in T2D and obese individuals.11,12”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, weight reduction can markedly improve blood sugar control and decrease the risk of cardiovascular disease [40].”
From The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Better glycaemic control has been reported in T2D patients who have lost weight, and excess body weight is associated with the risk of cardiometabolic complications, which are major causes of morbidity and mortality in T2D and obese individuals.11,12”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [11]
In the citing paper
“Weight loss is associated with an improved prognosis for overweight T2D patients and obese individuals.”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [11]
In the citing paper
“Weight loss was significantly associated with small reductions in both SBP and DBP in all treatment groups.”
From Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment: A Position Paper of The Obesity Society and the American Society of Hypertension (2013) · cites this paper as [208]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“At high concentrations they also slow gastric emptying and reduce food intake (16).”
BackgroundReduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes
The Look AHEAD Research Group (2007) · Diabetes Care · doi:10.2337/dc07-0048 · Cited by 1,522 · cited 1×
“improves lipid levels (9), and even a mod-”
BackgroundBeneficial health effects of modest weight loss.
Dj, G. (1992) · PubMed · Cited by 1,263
Aschner, P., Kipnes, M. S., Lunceford, J. K., Sanchez, M., Mickel, C., Williams-Herman, D. E., & for the Sitagliptin Study 021 Group (2006) · Diabetes Care · doi:10.2337/dc06-0703 · Cited by 880
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · cited 2×
“Data from clinical trials with exenatide, a GLP-1 receptor agonist, suggest that it has potentially beneficial effects on biomarkers of cardiovascular risk in patients with type 2 diabetes, including lowering blood pressure and improving dyslipidemia (19).”
BackgroundMethodIncretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
The Diabetes Prevention Program Research Group (2005) · Diabetes Care · doi:10.2337/diacare.28.4.888 · Cited by 572
Intentional weight loss and mortality among overweight individuals with diabetes.
Williamson, D. F., Thompson, T. J., Thun, M., Flanders, D., Pamuk, E., & Byers, T. (2000) · Diabetes Care · doi:10.2337/diacare.23.10.1499 · Cited by 558
Research works printed but not linked: 1
- Bergenstal, 2009, Exenatide once weekly improved cardiometabolic risk factors in subjects with type 2 diabetes during one year of treatment, Diabetes, 58, A165
Cited by
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
Landsberg, L., Aronne, L. J., Beilin, L. J., Burke, V., Igel, L. I., Lloyd‐Jones, D., & Sowers, J. (2013) · The Journal of Clinical Hypertension · doi:10.1111/jch.12049 · Cited by 528
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Nyenwe, E. A., Jerkins, T. W., Umpierrez, G. E., & Kitabchi, A. E. (2011) · Metabolism · doi:10.1016/j.metabol.2010.09.010 · Cited by 343
Type 2 Diabetes Mellitus and Hypertension
Lastra, G., Syed, S., Kurukulasuriya, L. R., Manrique, C., & Sowers, J. R. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.09.005 · Cited by 307
Landsberg, L., Aronne, L. J., Beilin, L. J., Burke, V., Igel, L. I., Lloyd‐Jones, D., & Sowers, J. (2013) · Obesity · doi:10.1002/oby.20181 · Cited by 284
Monami, M., Ahrén, B., Dicembrini, I., & Mannucci, E. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12000 · Cited by 259
Zambrowicz, B., Freiman, J., Brown, P. M., Frazier, K. S., Turnage, A., Bronner, J., Ruff, D., Shadoan, M., Banks, P., Mseeh, F., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.58 · Cited by 243
Wang, B., Zhong, J., Lin, H., Zhao, Z., Yan, Z., He, H., Ni, Y., Liu, D., & Zhu, Z. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12085 · Cited by 225
Ma, X., Meng, J., Jia, M., Bi, L., Zhou, Y., Wang, Y., Hu, J., He, G., & Luo, X. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1898 · Cited by 200
“Because GLP‐1 and exendin‐4 were reported to have beneficial effects in reducing cholesterol and triglycerides in diabetic subjects,((46)) they are also likely to be promising agents to preventing osteopenia.”
BackgroundHayashi, T., Fukui, T., Nakanishi, N., Yamamoto, S., Tomoyasu, M., Osamura, A., Ohara, M., Yamamoto, T., Ito, Y., & Hirano, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0491-5 · Cited by 196
Krasner, N. M., Ido, Y., Ruderman, N. B., & Cacicedo, J. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097554 · Cited by 186
“Interestingly, several large-scale retrospective trials have shown that GLP-1 mimetic therapies improve biomarkers of cardiovascular disease (CVD) and diminish the incidence of CVD events [11,12,13,14].”
BackgroundCefalu, W. T., Leiter, L. A., de Bruin, T. W. A., Gause-Nilsson, I., Sugg, J., & Parikh, S. J. (2015) · Diabetes Care · doi:10.2337/dc14-0315 · Cited by 182
Cardiovascular effects of gliptins
Scheen, A. J. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.183 · Cited by 175
Dushay, J., Gao, C., Gopalakrishnan, G. S., Crawley, M., Mitten, E. K., Wilker, E., Mullington, J., & Maratos-Flier, E. (2012) · Diabetes Care · doi:10.2337/dc11-0931 · Cited by 150
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
De Block, C., Bailey, C., Wysham, C., Hemmingway, A., Allen, S. E., & Peleshok, J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14831 · Cited by 121
Goto, H., Nomiyama, T., Mita, T., Yasunari, E., Azuma, K., Komiya, K., Arakawa, M., Jin, W. L., Kanazawa, A., Kawamori, R., et al. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.12.131 · Cited by 125
Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
Levin, P. A., Nguyen, H., Wittbrodt, E., & Kim, S. C. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s130834 · Cited by 107
Ogawa, S., Ishiki, M., Nako, K., Okamura, M., Senda, M., Mori, T., & Ito, S. (2011) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.223.133 · Cited by 107
GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia
Nuche-Berenguer, B., Lozano, D., Gutiérrez-Rojas, I., Moreno, P., Mariñoso, M. L., Esbrit, P., & Villanueva-Peñacarrillo, M. L. (2011) · Journal of Endocrinology · doi:10.1530/joe-11-0015 · Cited by 96
Shi, L., Ji, Y., Jiang, X., Zhou, L., Xu, Y., Li, Y., Jiang, W., Meng, P., & Liu, X. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0177-4 · Cited by 91
“Long-term treatment with GLP-1 effectively improves severe obesity, hypertension, and lipid profiles, all of which are critical risk factors in the development of atherosclerosis [25-28].”
BackgroundTaher, J., Baker, C. L., Cuizon, C., Masoudpour, H., Zhang, R., Farr, S., Naples, M., Bourdon, C., Pausova, Z., & Adeli, K. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.09.005 · Cited by 90
Matthaei, S., Catrinoiu, D., Celiñski, A., Ekholm, E., Cook, W., Hirshberg, B., Chen, H., Iqbal, N., & Hansen, L. (2015) · Diabetes Care · doi:10.2337/dc15-0811 · Cited by 91
Cardiovascular Effects of Glucagonlike peptide–1 Agonists
Davidson, M. H. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.046 · Cited by 88
Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide
Candeias, E. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.807 · Cited by 83
Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes
Scheen, A. J. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2659 · Cited by 82
Recent advances in incretin‐based therapies
Russell-Jones, D. L., & Gough, S. C. L. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04483.x · Cited by 82
Zhong, J., Gong, Q., Goud, A., Srinivasamaharaj, S., & Rajagopalan, S. (2015) · Journal of Diabetes Research · doi:10.1155/2015/606031 · Cited by 72
AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
Lu, Q., Li, X., Liu, J., Sun, X., Rousselle, T., Ren, D., Tong, N., & Li, J. (2019) · Bioscience Reports · doi:10.1042/bsr20181995 · Cited by 69
Chrysant, S. G., & Chrysant, G. S. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.01.398 · Cited by 71
Zhang, J., Chen, Q., Zhong, J., Liu, C., Zheng, B., & Gong, Q. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01050 · Cited by 62
Cystic Fibrosis Related Diabetes (CFRD)—The End Stage of Progressive Insulin Deficiency
Hameed, S. A., Jaffé, A., & Verge, C. F. (2011) · Pediatric Pulmonology · doi:10.1002/ppul.21495 · Cited by 53
Apolipoprotein A-I interactions with insulin secretion and production
Rye, K., Barter, P. J., & Cochran, B. J. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000253 · Cited by 55
Wadi, N. M., Asantewa-Ampaduh, S., Rivas, C. A., & Goff, L. M. (2021) · Public Health Nutrition · doi:10.1017/s1368980021003682 · Cited by 86
The cardiovascular safety of incretin-based therapies: a review of the evidence
Petrie, J. R. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-130 · Cited by 45
Ezzati, A., Rosenkranz, S. K., Phelan, J., & Logan, C. (2023) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2022.09.013 · Cited by 45
Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
Avogaro, A., Kreutzenberg, S., & Fadini, G. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990474 · Cited by 45
Hu, M., Cai, X., Yang, W., Zhang, S., Nie, L., & Ji, L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015323 · Cited by 48
Derosa, G., Ragonesi, P. D., Fogari, E., Cicero, A. F. G., Bianchi, L., Bonaventura, A., Romano, D., & Maffioli, P. (2012) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12001 · Cited by 50
Johansson, L., Hockings, P. D., Johnsson, E., Dronamraju, N., Maaske, J., Garcia‐Sanchez, R., & Wilding, J. P. H. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14004 · Cited by 41
Savarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 48
Herzlinger, S., & Horton, E. S. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.11.009 · Cited by 46
Self-citationPharmacological management of obesity an endocrine society clinical practice guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · Reproductive Endocrinology · doi:10.18370/2309-4117.2015.23.59-63 · Cited by 41
Koubaa, F. G., Chaâbane, M., Turki, M., Ayadi, F. M., & Feki, A. E. (2020) · Journal of Food Biochemistry · doi:10.1111/jfbc.13160 · Cited by 46
High protein diet is of benefit for patients with type 2 diabetes: An updated meta-analysis
Zhao, W.-T., Luo, Y., Zhang, Y., Zhou, Y., & Zhao, T.-T. (2018) · Medicine · doi:10.1097/md.0000000000013149 · Cited by 38
“Weight management is a major component of effective diabetes care, which can significantly improve the cardiovascular diseases markers (such as blood pressure, high-density lipoprotein cholesterol [HDL], and triglycerides [TG]) and glycemic control.([6,7]) Thus, long-term weight management is essential for the patient…”
BackgroundGlucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus: A Role in Cardiovascular Disease
Smilowitz, N. R., Donnino, R. M., & Schwartzbard, A. Z. (2014) · Circulation · doi:10.1161/circulationaha.113.006985 · Cited by 43
Wadi, N., Asantewa-Ampaduh, S., Rivas, C. A., & Goff, L. (2022) · UCL Discovery (University College London) · Cited by 37
Pleiotropic effects of incretins
Gupta, V. (2012) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.94259 · Cited by 36
Umpierrez, G. E., Pantalone, K. M., Kwan, A. Y. M., Zimmermann, A. G., Zhang, N., & Fernández Landó, L. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12660 · Cited by 36
Trajectories of BMI change impact glucose and insulin metabolism
Walsh, E., Shaw, J. E., & Cherbuin, N. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.12.003 · Cited by 40
Glycemic Variability in Type 2 Diabetes Mellitus: Oxidative Stress and Macrovascular Complications
Johnson, E. L. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5441-0_13 · Cited by 38
The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit
Ryder, R. E. J., Thong, K. Y., CULL, M. L., Mills, A., Walton, C., & Winocour, P. H. (2010) · Practical Diabetes · doi:10.1002/pdi.1522 · Cited by 33
Hasegawa, Y., Hori, M., Nakagami, T., Harada‐Shiba, M., & Uchigata, Y. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.11.006 · Cited by 33
The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome
Dawson, A. J., Sathyapalan, T., Vince, R., Coady, A.-M., Ajjan, R. A., Kilpatrick, E. S., & Atkin, S. L. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00189 · Cited by 33
Comparison of liraglutide versus other incretin‐related anti‐hyperglycaemic agents
Blonde, L., & Montanya, E. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01575.x · Cited by 34
Diabetes and Cardiovascular Disease: The Potential Benefit of Incretin-Based Therapies
Addison, D., & Aguilar, D. A. (2010) · Current Atherosclerosis Reports · doi:10.1007/s11883-010-0153-0 · Cited by 36
Fan, M., Li, Y., & Zhang, S. (2016) · Medicine · doi:10.1097/md.0000000000002386 · Cited by 38
Hollander, P., Lasko, B., Barnett, A. H., Bengus, M., Kanitra, L., Pi‐Sunyer, F. X., & Balena, R. (2013) · Obesity · doi:10.1002/oby.20042 · Cited by 30
Cardiovascular Actions of GLP-1 and Incretin-Based Pharmacotherapy
Avogaro, A., de Kreutzenberg, S. V., & Fadini, G. P. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0483-3 · Cited by 30
Advances in the detection and management of cystic fibrosis related diabetes
Hameed, S. A., Jaffé, A., & Verge, C. F. (2015) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000251 · Cited by 30
Yang, J., Xia, Y., Sun, Y., Guo, Y., Shi, Z., Moreira, N. C. D. V., Zuo, H., & Hussain, A. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110662 · Cited by 38
Henry, R. R., Mudaliar, S., Kanitra, L., Woloschak, M., Balena, R., & for the T-Emerge 3 Study Group (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3253 · Cited by 29
Ankarfeldt, M., Adalsteinsson, E., Groenwold, R., Ali, M. S., & Klungel, O. (2016) · Clinical Epidemiology · doi:10.2147/clep.s121991 · Cited by 25
Cao, Q., Xu, D., Chen, Y., Long, Y., Dai, F., Gui, L., & Lu, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.670389 · Cited by 28
Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes
Chaudhuri, A., & Dandona, P. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01423.x · Cited by 28
Incretin-based therapies: can we achieve glycemic control and cardioprotection?
Angeli, F. S., & Shannon, R. P. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0195 · Cited by 30
Clinical Implications of Exenatide as a Twice-Daily or Once-Weekly Therapy for Type 2 Diabetes
Aroda, V. R., & DeYoung, M. B. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.09.2479 · Cited by 27
Sharma, M., Beckley‐Hoelscher, N., Nazareth, I., & Petersen, I. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017260 · Cited by 28
Moraes, R. M., Lima, G. M., de Oliveira, F. E., Brito, A. C. V., Pereira, R. C., de Oliveira, L. D., de Barros, P. P., Franco, G. C. N., & Anbinder, A. L. (2015) · Journal of Periodontology · doi:10.1902/jop.2015.150278 · Cited by 31
Potenza, M. A., Nacci, C., Salvia, M. A. D., Sgarra, L., Collino, M., & Montagnani, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.04.009 · Cited by 26
Cardiovascular Effects of Anti-Diabetic Medications in Type 2 Diabetes Mellitus
Singh, S. B., Bhat, J., & Wang, P. H. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0327-1 · Cited by 23
Bain, S. C., Feher, M. D., Russell-Jones, D. L., & Khunti, K. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12760 · Cited by 27
Van Gaal, L., Souhami, E., Zhou, T., & Aronson, R. (2014) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2014.03.001 · Cited by 22
György, J., Gaál, Z., Gerő, L., Hídvégi, T., Kempler, P., Winkler, G., & Wittmann, I. (2017) · Diabetologia Hungarica · doi:10.24121/dh.2017.1 · Cited by 39
Best, J. H., Lavillotti, K., DeYoung, M. B., & Garrison, L. P. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01533.x · Cited by 21
Doustmohammadian, A., Nezhadisalami, A., Tameshkel, F. S., Motamed, N., Maadi, M., Farahmand, M., Sohrabi, M., Clark, C. C. T., Ajdarkosh, H., Faraji, A. H., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.937554 · Cited by 26
Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes
Donner, T. W., & Joseph, J. J. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s50286 · Cited by 22
Yousefzadeh, P., & Wang, X. (2013) · Journal of Diabetes Research · doi:10.1155/2013/459821 · Cited by 21
Yao, Y., Li, Q., Gao, P., Wang, W., Chen, L., Zhang, J., & Xu, Y. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.02.126 · Cited by 23
Igel, L. I., Powell, A. G., Apovian, C. M., & Aronne, L. J. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0221-0 · Cited by 22
Liu, L., Shi, H., Xie, M., Sun, Y., & Nahata, M. C. (2025) · Pharmaceuticals · doi:10.3390/ph18050668 · Cited by 19
Li, Z., Han, Z., Sun, R., Xuan, X., & Huang, C. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s539822 · Cited by 23
Potential cardiovascular effects of incretin-based therapies
Deacon, C. F., & Marx, N. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.5 · Cited by 19
Yokoh, H., Kobayashi, K., Sato, Y., Takemoto, M., Uchida, D., Kanatsuka, A., Kuribayashi, N., Terano, T., Hashimoto, N., Sakurai, K., et al. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12282 · Cited by 20
Premji, R., Nylen, E. S., Naser, N., Gandhi, S., Burman, K. D., & Sen, S. (2022) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2022.0004 · Cited by 18
“41 In one meta-analysis, HDL lowering was reported, 42 while another review revealed a neutral effect.”
Rivera, F. B., Chin, M. N. C., Pine, P. L. S., Ruyeras, M. M. J., Galang, D. J. C., Gandionco, K. M., Morales, B. L. F. D., Climaco, Z. M. V., Bantayan, N. R. B., Magalong, J. V., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2442027 · Cited by 19
Shinde, S., Thieu, V. T., Kwan, A. Y. M., Houghton, K., Meyers, J., & Schapiro, D. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01511-4 · Cited by 19
Pawaskar, M. D., Li, Q., Hoogwerf, B. J., Reynolds, M. W., Faries, D. E., Engelman, W., Bruhn, D. F., & Bergenstal, R. M. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01581.x · Cited by 15
Clinical applications of advanced lipoprotein testing in diabetes mellitus
Moin, D. S., & Rohatgi, A. K. (2011) · Clinical Lipidology · doi:10.2217/clp.11.37 · Cited by 19
Potential cardioprotective action of GLP-1: from bench to bedside
Aronis, K. N., Tsoukas, M. A., & Mantzoros, C. S. (2014) · Metabolism · doi:10.1016/j.metabol.2014.05.009 · Cited by 14
Muzurović, E. M., Dragnić, S., Medenica, S., Smolović, B., Bulajić, P., & Mikhailidis, D. P. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107619 · Cited by 17
Fridman, M., Lucas, M. E., Paprocki, Y., Dang‐Tan, T., & Iyer, N. N. (2020) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s266873 · Cited by 17
le Roux, C. W., & Mondoh, A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2311731 · Cited by 16
Lebovitz, H. E., & Banerji, M. A. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0022 · Cited by 14
Ross, S. A. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.973939 · Cited by 12
Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview
Robertson, C. (2011) · Diabetes Spectrum · doi:10.2337/diaspect.24.1.26 · Cited by 14
on behalf of the EpiDREAM and INTERHEART investigators, Bailey, S. D., Xie, C., Paré, G., Montpetit, A., Mohan, V., Yusuf, S., Gerstein, H. C., Engert, J. C., & Anand, S. S. (2013) · Diabetologia · doi:10.1007/s00125-013-3142-3 · Cited by 13
Soejima, H., Ogawa, H., Morimoto, T., Okada, S., Matsumoto, C., Nakayama, M., Masuda, I., Jinnouchi, H., Waki, M., Saito, Y., et al. (2023) · Heart and Vessels · doi:10.1007/s00380-023-02291-4 · Cited by 12
Bedros, J. R., Jermendy, G., Gaál, Z., Gerő, L., Hídvégi, T., Kempler, P., Lengyel, C., Várkonyi, T. T., Winkler, G., & Wittmann, I. (2023) · Diabetologia Hungarica · doi:10.24121/dh.2023.20 · Cited by 21
Metadata
- Authors
- Horton, E. S., Silberman, C., Davis, K. L., & Berria, R.
- Affiliations
- Joslin Diabetes Center (US)
- Roche Laboratories, Nutley, New Jersey; and
- RTI Health Solutions (US)
- Corresponding author
- Horton, Edward S.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2010-05-11
- Volume
- 33
- Issue
- 8
- Pages
- 1759-1765
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2909058
- OpenAlex
- W2099903872
- Cited by
- 156
- References
- 23
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 3 · 2023: 5 · 2022: 7 · 2021: 8 · 2020: 6 · 2019: 7 · 2018: 2 · 2017: 14 · 2016: 9 · 2015: 13 · 2014: 16 · 2013: 15 · 2012: 21
- FWCI
- 14.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- type 2 diabetes, weight loss, glycemic control, GLP-1 receptor agonists, exenatide, sitagliptin, insulin therapy, cardiovascular risk markers, blood pressure, dyslipidemia, HbA1c, fasting blood glucose, lipid profile
- MeSH terms
- Sitagliptin Phosphate, Exenatide, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Peptides, Pyrazines, Triazoles, Venoms, Cohort Studies, Weight Loss, Multivariate Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.